Loading company…
Nemesis develops semiconductor chips for biosignal processing and medical diagnostic equipment.
Founded in 2017 and based in Gyeonggi-do, South Korea, Nemesis develops biosignal processing semiconductors for medical devices and diagnostics. Its products include the NMS4110 for electrochemical sensing, the NMI1000 for image sensing and capsule endoscopy, and the NMS3150 for force and torque sensing. In June 2021, it raised KRW 2.5 billion in pre-Series A funding led by Capstone Partners, KGround Ventures, and UTC Investment.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in